Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Discontinuation rate and reason for discontinuation after sodium-glucose cotransporter 2 inhibitor prescription in real clinical practice

Authors
Kim, HyunahLee, Seung-HwanCho, Jae-HyoungLee, HyunyongYim, Hyeon WooYoon, Kun-HoKim, Hun-Sung
Issue Date
Dec-2020
Publisher
WILEY
Keywords
dapagliflozin; real-world data; real-world evidence; SGLT2i; side effects
Citation
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, v.45, no.6, pp.1271 - 1277
Journal Title
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Volume
45
Number
6
Start Page
1271
End Page
1277
URI
https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/1017
DOI
10.1111/jcpt.13205
ISSN
0269-4727
Abstract
What is known and objectives Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are novel antidiabetic agents that have advantages of weight loss and prevention of cardiovascular diseases. However, SGLT2i have various side effects. To understand their effectiveness, we analysed patients who had discontinued the use of dapagliflozin, an SGLT2i, 3 months after the initial prescription. We evaluated the discontinuation rate of dapagliflozin and the incidence rate of its side effects. Methods Patients who were initially prescribed dapagliflozin for blood sugar control from December 2014 to December 2016 were analysed. Data of patients in whom dapagliflozin administration was discontinued 90 days after initial prescription were collected separately, and the reasons were evaluated by a direct chart review. Results and discussion A total of 8.96% (149/1663) patients discontinued dapagliflozin or switched medications within 3 months. Dapagliflozin was discontinued in 24.8% (37/149) of cases due to unexpected causes such as increased blood sugar and weight gain. The patients who discontinued dapagliflozin use due to side effects comprised 49.7% (74/149). Two major side effects were genital tract infection in women (P < .001 compared with men) and urinary tract infection, which increased with age (P = .030). Malpractice of medical personnel, insurance problems or causes of termination not related to dapagliflozin use comprised 14.1% (21/149). What is new and conclusion The incidence of side effects with dapagliflozin was not as high as expected. Physicians should consider instructions prior to prescribing dapagliflozin so that its discontinuation would decrease considerably.
Files in This Item
Go to Link
Appears in
Collections
약학대학 > 약학부 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Hyun Ah photo

Kim, Hyun Ah
약학대학 (약학부)
Read more

Altmetrics

Total Views & Downloads

BROWSE